Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of intrathecal tominersen in Huntington's disease
NL-OMON55276Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Feb 2021
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of tominersen in Huntington disease (HD) (2 arms), sponsored by Roche. Primary endpoints: Incidence and severity of adverse events, Change from baseline in targeted vital signs and 8 more. Started Feb 2021; status: active, not recruiting.
02
Drugs
tominersen
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NL-OMON55276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55276.